Because these mechanisms may collectively contribute to tumor progression in conditions of reduced perfusion, understanding the effects of COX-2 inhibitors during VEGF blockade may hold promise for improving the usefulness of this treatment strategy. This evidence concerns the gene PTGS2 and neoplasm.